Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Merck
Baxter
Moodys

Last Updated: June 30, 2022

Investigational Drug Information for GDC-0810


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for GDC-0810?

GDC-0810 is an investigational drug.

There have been 184 clinical trials for GDC-0810. The most recent clinical trial was a Phase 3 trial, which was initiated on January 8th 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are nine US patents protecting this investigational drug and one hundred and forty-two international patents.

Recent Clinical Trials for GDC-0810
TitleSponsorPhase
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)Phase 1/Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2

See all GDC-0810 clinical trials

Clinical Trial Summary for GDC-0810

Top disease conditions for GDC-0810
Top clinical trial sponsors for GDC-0810

See all GDC-0810 clinical trials

US Patents for GDC-0810

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0810 See Plans and Pricing Estrogen receptor mutations and uses thereof FOUNDATION MEDICINE, INC. (Cambridge, MA) See Plans and Pricing
GDC-0810 See Plans and Pricing Heteroaryl estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
GDC-0810 See Plans and Pricing Polymorphic forms of RAD1901-2HCl RADIUS PHARMACEUTICALS, INC. (Waltham, MA) See Plans and Pricing
GDC-0810 See Plans and Pricing Soft gelatin capsule formulation KaNDy Therapeutics Limited (Stevenage Herts, GB) See Plans and Pricing
GDC-0810 See Plans and Pricing Estrogen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA) See Plans and Pricing
GDC-0810 See Plans and Pricing Estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0810

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0810 Australia AU2014358850 2033-12-06 See Plans and Pricing
GDC-0810 Canada CA2932106 2033-12-06 See Plans and Pricing
GDC-0810 China CN105916501 2033-12-06 See Plans and Pricing
GDC-0810 European Patent Office EP3089747 2033-12-06 See Plans and Pricing
GDC-0810 Hong Kong HK1223557 2033-12-06 See Plans and Pricing
GDC-0810 Israel IL245758 2033-12-06 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.